Articles tagged with Leukemia
Researchers developed a new personalized test for monitoring cancer recurrence in acute lymphoblastic leukemia (ALL) patients. The MP PCR uses multiple genomic markers to detect disease recurrence sooner, improving treatment strategies and patient stratification.
Scientists at St. Jude Children's Research Hospital and the Cancer Research Center in Spain have discovered a potential strategy to prevent B-ALL, the most common childhood cancer, using the drug ruxolitinib. By blocking IL-7 signaling, researchers were able to significantly reduce the risk of leukemia development in genetically predis...
Researchers at UT Health San Antonio have discovered that specific RNA molecules can bind to and inhibit the activity of two proteins (METTL-3 and METTL-14) that drive DNA changes in leukemia. This finding provides a potential therapeutic target for treating this cancer.
Researchers discovered two patients with CAR T cell therapy achieved the longest-known remission to date, providing new details about treatment effects and outcomes. The study shows that the infused CAR T cells remained detectable for at least a decade, with sustained remission in both patients.
Researchers have developed a personalized dosing regime for anti-thymocyte globulin (ATG) to improve the success of stem cell transplants in children with leukemia. The new approach led to better immune recovery and higher survival rates compared to standard treatment.
Sophie Paczesny's research aims to validate biomarker panels that help doctors predict chronic GVHD risk and adjust immune suppression treatments accordingly. The study uses machine learning algorithms to analyze stored plasma and blood cell samples from over 1,300 BMT recipients.
Survival rates for adult patients with relapsed acute lymphoblastic leukemia (ALL) after hematopoietic cell transplantation have increased significantly over the past two decades. The two-year overall survival rate rose from 27.8% in 2000-2004 to 54.8% in 2015-2019, despite a significant increase in patient age at relapse.
A new graft strategy has reduced chronic graft-versus-host disease in leukemia patients by depleting naïve T cells from donor blood. The approach has shown promising results, with only 7% of patients developing chronic GVHD compared to 30-60% with standard treatment.
Researchers discovered that aberrant splicing of CD22 mRNA leads to decreased protein expression in pediatric B-lymphoblastic leukemia cells. This results in resistance to CD22-directed immunotherapies, making it challenging for oncologists to identify patients who may not respond to these treatments.
A new study published in Nature found that valine is essential for the growth of T cell acute lymphoblastic leukemia, a type of childhood blood cancer. Blocking valine-linked genes led to decreased valine levels and stalled tumor cells from growing.
Researchers found that mutations in IL-7R are sufficient to trigger acute lymphoblastic leukemia, a common and aggressive cancer in children. The study suggests that drugs targeting this protein may offer new therapeutic options for patients.
A new treatment combination of dasatinib, blinatumomab, and prednisone has shown promise in treating older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. The trial achieved a three-year DFS rate of 80 percent and an overall survival rate of 85 percent for enrolled patients.
A recent study published in JNCCN found that only 31% of hospitals have immediate availability of all-trans retinoic acid (ATRA), a crucial blood cancer medication. This medication is essential for treating acute promyelocytic leukemia, which has a better prognosis when treated appropriately. The lack of ATRA availability poses a signi...
This study found high expression of Myosin 1g in pediatric acute lymphoblastic leukemia, suggesting its potential role in disease pathogenesis, particularly in high-risk patients. The research also showed that Myo1g may serve as a biomarker for identifying patients with an increased risk of relapse.
A new study by USC researchers uses a genetic technology to analyze gene expression signatures of individual cancer cells from patients with leukemia. The findings show that cancer cells with distinct gene expression profiles tend to grow in different organs, while those with specific genes are more resistant to chemotherapy.
A study suggests that suppressing the protective mechanisms of rogue blood stem cells can help curb clonal hematopoiesis and prevent leukemia. The researchers used zebrafish with colored 'barcodes' to track the dominance of cancerous clones, revealing a connection between anti-inflammatory genes and resistance to inflammation.
Researchers found that inhibiting the MAP2K7-JNK pathway with 5Z-7-oxozeaenol induces apoptosis in T-cell acute lymphoblastic leukemia. The study used murine models and human patient-derived xenografts to evaluate the anti-leukemic capacity of 5Z7O, which showed synergistic induction of cytotoxicity when combined with dexamethasone.
Researchers have developed a ferritin-based nanomedicine that targets diverse leukemia types, improving therapeutic efficacy and reducing toxicity. The nanomedicine delivers arsenic to leukemia cells, enhancing killing effects while minimizing harm to normal tissues.
Researchers discovered that skin-derived T cells can migrate into the bloodstream and cause inflammation in other organs, such as the intestine. The study provides new approaches to therapy and diagnostic options for stem cell transplantation.
Researchers conducted a functional test to identify effective therapies for advanced hematological cancers, achieving significant positive outcomes with 56 patients receiving individually tailored treatment. The study demonstrates the clinical feasibility and efficacy of personalized medicine in breaking resistance to prior therapies.
MUSC researcher Haizhen Wang receives R37 grant to investigate CDK6's role in T-cell acute lymphoblastic leukemia, a aggressive cancer. The research aims to understand how the immune system can be used to reduce leukemia progression.
A new study published in the Lancet Haematology found that children with Down syndrome are more likely to develop aggressive forms of leukemia and have a poorer prognosis. The research also identified potential differences in treatment outcomes between children with and without Down syndrome.
Researchers at the University of Basel have discovered a novel combination therapy approach that combines inhibiting JAK2 with targeting the MAPK signaling pathway. This dual targeting strategy has shown promising results in improving leukemia treatment outcomes by reducing blood cell production and altering disease course.
Children genetically predisposed to overproduce lymphocytes in relation to other white blood cells are at higher risk of developing ALL, according to a new USC study. The research found that the ratio of lymphocytes to other key blood cells is significant in predicting leukemia risk.
Researchers found no significant DNA changes in stem cells after transplant, but an anti-virus drug called ganciclovir may contribute to cancer development. Further research is needed to investigate this further.
A study from Linköping University found that the tumour-inhibiting gene TET2 is silenced in most cases of acute lymphoblastic leukemia (ALL) in children. The gene can be reactivated by treatment with an existing drug, 5-azacytidine, suggesting a targeted therapy for ALL in children.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Fels and Fox Chase researchers found specific TET2 and DNMT3A mutations in leukemia patients that affect DNA repair pathways. These mutations make leukemia cells sensitive to PARP inhibitors, a type of targeted therapy, while others are resistant. The study aims to develop personalized therapies for patients with these mutations.
A large phase 3 noninferiority clinical trial showed that omitting pulse therapy in patients with low-risk disease improves quality of life without affecting survival. This finding is significant as it reduces neuropsychological side effects and late effects associated with long-term treatment.
Researchers have discovered protein markers related to chronic lymphocytic leukemia (CLL), a common form of leukemia. The markers can help determine patients' prognoses and point to potential therapeutic targets.
Researchers in China have created a novel risk score to predict relapse of leukemia, allowing for better medical intervention and stratification of patients with different risks. The study analyzed factors such as engraftment of white blood cells, residual cancer cells, and chronic graft-versus-host disease to determine outcomes like 5...
Researchers at University of Texas M. D. Anderson Cancer Center found that combination ibrutinib and venetoclax provided lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), with a three-year overall survival rate of 96%
A team of researchers has developed first-in-class small molecules to inhibit the SET domain of the ASH1L protein, preventing critical molecular interactions in leukemia development. The lead compound, AS-99, successfully reduced leukemia progression in mouse models.
Researchers at Johns Hopkins Medicine used information theory to identify a likely key genetic culprit in acute lymphoblastic leukemia (ALL), the most common form of childhood leukemia. By analyzing DNA methylation patterns, they discovered a gene called UHRF1 that drives the development of cancer.
Researchers at Tokyo Medical and Dental University developed an antibody-drug conjugate that selectively targets human monocyte progenitors to combat chronic myelomonocytic leukemia (CMML). This strategy effectively blocks malignant cell proliferation with minimal collateral damage to other cell lineages.
A low-calorie diet and moderate exercise program have been shown to dramatically improve survival outcomes for young people with acute lymphoblastic leukemia. After just one month of treatment, participants on the intervention had a 70% decrease in detectable cancer cells compared to those not on the regimen.
Researchers found that genetic mutations, such as IKZF1 deletion and CRLF2 translocations, occur more frequently in Hispanic and Latino children with B-cell acute lymphoblastic leukemia (B-ALL), leading to poorer outcomes. A novel therapeutic drug combination may help address this disparity.
A novel metabolic gatekeeper mechanism for leukemia has been discovered by Yale researchers, highlighting the importance of glucose and energy supply in leukemic transformation. High expression levels of PON2 enable glucose uptake activity in B-cell acute lymphoblastic leukemia cells, leading to a more aggressive course of disease.
Researchers have discovered that two anti-viral enzymes, APOBEC3C and ADAR1, fuel the transition from pre-cancer stem cells to leukemia stem cells. Inhibiting these enzymes with existing medications may help prevent cancer, including leukemia.
The study showed that the combination of chemotherapy and blinatumomab resulted in increased survival rates and achieved a high rate of MRD negativity for patients with Ph-negative B-cell ALL. This treatment approach has the potential to improve long-term outcomes for these patients.
A study by Octapharma at ASH found that high-dose Octagam 10% IVIg significantly improved hypoxia and reduced hospital length of stay in COVID-19 patients with pneumonia. A larger multicenter study is underway to determine if the therapy can slow or stop respiratory deterioration.
MUSC researchers discovered blocking an energy pathway for T-cells after hematopoietic stem cell transplant reduces graft-versus-host disease, while maintaining ability to kill leukemia cells. The study uses a lysosomal acid lipase-deficient mouse model, showing promising results with FDA-approved inhibitor orlistat.
Researchers have identified a new and evolutionarily conserved pathway responsible for silencing genes in mammalian cells. BAHCC1 protein is involved in the Polycomb pathway, which generates a chemical tag to silence genes, and its high expression is linked to leukemia, challenging current understanding of gene silencing.
Researchers have developed a new type of precise therapeutic vaccine against leukemia utilizing self-healing polylactic acid microcapsules. The vaccine co-encapsulates a new epitope peptide and PD-1 antibody, demonstrating superior performance over commercialized adjuvants in various models.
Researchers at Temple University Health System discovered a mechanism behind drug resistance in leukemia cells and found that combining PARP inhibition with TGFBR kinase blockade can overcome resistance. This breakthrough could lead to a new treatment strategy for leukemia patients.
Researchers identified a second path to defeating chronic myelogenous leukemia by disrupting the Gdpd3 gene, which regulates quiescence of CML stem cells. This approach reduces leukemia relapse rates even when BCR-ABL1 oncogene is not disrupted.
Scientists have identified new genes that are overexpressed in endothelial cells of people with Down syndrome, increasing their risk for leukemia. The study suggests these genes could be therapeutic targets for developing novel treatments and prevention strategies.
A study published in Nature found that blood cell mutations linked to leukemias become inevitable as people age, especially in the Japanese population. The research identified genetic variations associated with increased risk of these mutations, which can be detected through a simple blood test.
UConn researchers use patented nanoparticle with common chemotherapy drug doxorubicin to target leukemia stem cells, reducing treatment-resistant relapses. The nanoparticle enables slow release of the drug to bone marrow, improving survival rates and inhibiting cancerous stem cells.
Scientists create super-powered natural killer cells by deleting an inhibitory gene, resulting in improved anti-tumor activity and persistence. The modified cells also exhibit enhanced metabolic reprogramming and energy utilization, leading to more effective cancer treatment.
The E1912 trial showed that the ibrutinib-rituximab combination provided better leukemia control, prolonged life, and had fewer side effects compared to standard care in untreated patients with chronic lymphocytic leukemia. The FDA approval is based on data from the phase 3 trial developed by the ECOG-ACRIN Cancer Research Group.
Scientists have engineered T-cells to target multiple sites on leukemia cells, offering a more effective treatment for resistant acute lymphoblastic leukemia. The new CAR-T therapy, TriCAR T-cells, targeting CD-19/20/22, demonstrate improved efficacy compared to single-antigen therapies.
Researchers found that structural changes in protein bundles called chromosomes affect access to genes in T cell acute lymphoblastic leukemia. The new work shows that altering the 3D architecture of chromosomes can trigger cancer growth and spread, making targeted therapy a promising approach.
Researchers at Nemours have identified new genetic structural variants in childhood leukemia that can help assess minimal residual disease during chemotherapy. This breakthrough could lead to more precise diagnosis and targeted therapies for kids with cancer, improving treatment outcomes.
Researchers identified subpopulations of leukemia cells present at diagnosis that have distinct characteristics, leading to relapse in children and adults. These findings provide new avenues for overcoming resistance and improving treatment approaches.
The CD19 CAR NK-cell therapy achieved a 73% response rate in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities reported. The treatment was administered in an outpatient setting, and responses were evident within one month following infusion.
Chronic lymphocytic leukemia (CLL) patients respond differently to ibrutinib treatment due to individual genetic and epigenetic profiles. The study reveals a shared genetic program in CLL cells responding to ibrutinib, but with patient-specific execution, leading to varying disease progression rates.
A collaborative clinical trial has led to changes in the treatment of leukemia driven by the Philadelphia chromosome, a high-risk subtype associated with poor outcomes. Dasatinib was found to provide greater benefit than the standard of care, resulting in improved event-free survival rates.
Researchers have identified a promising drug candidate OT-82 that demonstrates remarkable efficacy in preclinical models. It targets the NAMPT enzyme responsible for NAD production, showing potential as a novel treatment option for refractory blood cancers.